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Abstract
Background: Non-psychotropic atypical cannabinoids have therapeutic potential in a variety of inflammatory
conditions including those of the gastrointestinal tract. Here we examined the effects of the atypical cannabinoid
abnormal cannabidiol (Abn-CBD) on wound healing, inflammatory cell recruitment and colitis in mice.
Methods: Colitis was induced in CD1 mice by a single intrarectal administration of trinitrobenzene sulfonic acid
(TNBS, 4 mg/100 μl in 30 % ethanol) and Abn-CBD and/or the antagonists O-1918 (Abd-CBD), AM251 (CB1 receptor)
and AM630 (CB2 receptor), were administered intraperitoneally (all 5 mg/kg, twice daily for 3 days). The degree of
colitis was assessed macro- and microscopically and tissue myeloperoxidase activity was determined. The effects of
Abn-CBD on wound healing of endothelial and epithelial cells (LoVo) were assessed in a scratch injury assay.
Human neutrophils were employed in Transwell assays or perfused over human umbilical vein endothelial cells
(HUVEC) to study the effect of Abn-CBD on neutrophil accumulation and transmigration.
Results: TNBS-induced colitis was attenuated by treatment with Abn-CBD. Histological, macroscopic colitis scores
and tissue myeloperoxidase activity were significantly reduced. These effects were inhibited by O-1918, but not by
AM630, and only in part by AM251. Wound healing of both HUVEC and LoVo cells was enhanced by Abn-CBD.
Abn-CBD inhibited neutrophil migration towards IL-8, and dose-dependently inhibited accumulation of neutrophils
on HUVEC.
Conclusions: Abn-CBD is protective against TNBS-induced colitis, promotes wound healing of endothelial and
epithelial cells and inhibits neutrophil accumulation on HUVEC monolayers. Thus, the atypical cannabinoid Abn-CBD
represents a novel potential therapeutic in the treatment of intestinal inflammatory diseases.
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Background
Cannabis has long been recognized in the Western world
for its analgesic, appetite stimulant, antiemetic, muscle re-
laxant and anticonvulsant properties [1]. Today it is
known that plant-derived cannabinoids, or phytocannabi-
noids, such as Δ9-tetrahydrocannabinol (Δ9-THC) and
cannabinol exert their therapeutic effects through the
cannabinoid 1 (CB1) and CB2 receptors of the endocan-
nabinoid system [2]. Extracts of Cannabis have been
used as therapeutics in gastrointestinal disorders, but
the major pharmacologically active component, Δ9-THC
has psychotropic properties which limit its suitability as a
drug [3].
Aiming to circumvent the psychotropic side effects of
cannabis, researchers have focused on the therapeutic
potential of non-psychotropic cannabinoids, such as the
phytocannabinoid cannabidiol (CBD). CBD has been
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shown to attenuate experimental colitis in mice, when
administered topically or systemically [4]. In addition,
the anti-inflammatory and modest antioxidant properties
of CBD make it a promising candidate for drug develop-
ment to target a number of systemic diseases, including
rheumatoid arthritis and atherosclerosis [5]. Using CBD
as the prototype, synthetic analogs have been developed
such as the regio-isomer abnormal cannabidiol (Abn-CBD)
and it’s close relative O-1602. These ‘atypical’ cannabinoids
lack significant binding affinity to cannabinoid receptors,
but act on novel targets such as the orphan receptor
GPR55 [6, 7]. It has been demonstrated that CBD and O-
1602 protect against experimentally induced colitis in mice,
but their mechanisms of action requires further investiga-
tion, notably, as the protective properties of O-1602 are also
observed in mice lacking the GPR55 gene [8, 9]. They
might be conferred by GPR18, another target of O-1602
and the putative receptor of Abn-CBD [10]. While studies
have examined the vasodilatory and neuroprotective effects
of Abn-CBD [7, 11–13], its potential role in the modulation
of gastrointestinal inflammation has not been examined.
The aim of this study was to examine if the CBD analogue
Abn-CBD has therapeutic potential in the treatment of
gastrointestinal inflammation. We tested the hypothesis that
Abn-CBD would reduce intestinal inflammation and accel-
erate epithelial would healing. We first examined the
therapeutic effect of Abn-CBD in a murine model of
experimentally induced colitis. The Abn-CBD receptor
antagonist O-1918, and the CB1 and CB2 receptor antago-
nists, AM251 and AM630, respectively, were employed in
order to elucidate, if Abn-CBD effects were CB1/CB2
dependent or conferred by other receptors. Next we exam-
ined the effects of the Abn-CBD on neutrophil recruitment,
an important cellular mechanism of intestinal inflamma-
tion. Lastly, we studied the impact of Abn-CBD on endo-
thelial and epithelial wound healing in vitro, to address a
further potential therapeutic mechanism of action [14, 15].
Methods
Mice
Male CD1 mice (3 weeks old, weighing ~16 g) were pur-
chased from Charles River (Saint-Constant, Quebec,
Canada) and kept in-house for 2 weeks prior to experi-
ments. Mice were housed in plastic sawdust floor cages
at constant temperature (22 °C) and a 12:12-h light–dark
cycle with access to standard laboratory chow and tap
water ad libitum. Experimental procedures were approved
by the University of Calgary Animal Care Committee and
conducted according to guidelines of the Canadian Coun-
cil on Animal Care.
Drugs and Pharmacological Treatments
Trinitrobenzene sulfonic acid (TNBS) was purchased from
Sigma-Aldrich (Oakville, Ontario, Canada). Abn-CBD,




methanone) and AM251 (N-(Piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-
3-carboxamide) were obtained from Tocris Bioscience
(Bristol, UK). Because of its toxicity, methyl acetate was
evaporated prior to the in vivo experiments and ethanol
was used instead as a solvent. Abn-CBD was then further
diluted in Tween 80 (10 %) and sterile saline. Vehicle con-
sisted of ethanol, Tween 80 and sterile saline (1:1:8).
AM630 and AM251 were dissolved in dimethyl sulfoxide
(DMSO, 99.7 %) and further diluted with vehicle. 45 min
prior to the induction of TNBS colitis, mice were injected
intraperitoneally (i.p.) with 5 mg/kg AM630, AM251, O-
1918 or vehicle, followed by 5 mg/kg Abn-CBD, 15 min
later. As a single dose of Abn-CBD was ineffective (prelim-
inary data not shown), mice were injected twice daily for
3 days. For in vitro assays, 10 mM stock solutions (in
DMSO) of Abn-CBD and the CB receptor antagonists
were prepared.
Induction of TNBS colitis
The TNBS colitis experiment was used as an established
model for testing cannabinoid effects on experimental
colitis [4, 9, 16]. TNBS colitis was induced in male CD1
mice as described previously [17]. Briefly, animals were
lightly anaesthetized with isoflurane and TNBS (4 mg in
100 μL of 30 % ethanol) was infused into the colon
through a catheter, 1 mm in diameter, inserted 3 cm
proximally to the anus in mice. Vehicle alone (100 μL of
30 % ethanol) was administered in control experiments.
The mice were weighed daily.
Macroscopic scoring and damage assessment
Four days after the induction of colitis, mice were eutha-
nized by cervical dislocation. The colon was immediately
removed, opened longitudinally along the mesenteric
border, and examined. Colonic damage was assessed by
a semi-quantitative scoring system as previously de-
scribed [9]. Macroscopic damage was scored according
to the following scale, adding individual scores for ulcer,
colonic shortening, wall thickness, and presence of
hemorrhage, fecal blood, or diarrhea. Ulcer: 1 point for
each 0.5 cm; shortening of the colon: 1 point = >15 %, 2
points = >25 % (based on a mean length of the untreated
colon of 7.6 ± 0.55 cm; n = 5-10); wall thickness mea-
sured in mm. The presence of hemorrhage, fecal blood,
or diarrhea increased the score by 1 point for each add-
itional feature. Adhesion of the colon to organs was
scored as follows: 1 point = 1 adhesion, 2 points = 2 or
more adhesions or adhesions to organs. A new batch of
TNBS was used for the experiments with the AM630
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and AM251 inhibitors, likely being the reason for the
higher overall damage score in these experiments.
Myeloperoxidase activity
Measurement of myeloperoxidase (MPO) activity in tis-
sue samples was used to assess the degree of granulocyte
infiltration [18]. Samples of mouse colon were weighed,
immediately frozen on dry ice, and stored at - 80 °C. For
determination of MPO activity, the frozen tissue was
placed in 0.5 % HTAB buffer (50 mg of tissue/mL;
pH 6.0) and disrupted with a Polytron homogenizer
(Brinkman Instruments, Mississauga, Ontario, Canada). The
detergent HTAB (hexadecyl-trimethyl-ammoniumbromide;
Sigma-Aldrich) releases MPO from the primary granules of
neutrophils and enhances enzyme activity through the
presence of bromide. Afterwards, the homogenate was
centrifuged for 15 min at maximum speed and 4 °C. Be-
fore reading MPO activity, 7 μL of supernatant was
added to 200 μL of 50 mM potassium phosphate buffer
(pH 6.0) containing 0.167 mg/mL of O-dianisidine
hydrochloride and 0.5 μL of 1 % H2O2/mL. The kinetics of
MPO activity was measured at 460 nm (Thermo Fischer
Labsystems Multiskan, Thermo Scientific, Ottawa, Ontario,
Canada). A mean was calculated for the vehicle-treated
group and set at 100 %. Values of all other treatment
groups are expressed as percent of the respective vehicle-
treated group (TNBS only).
Histology
For microscopic scoring, segments of the distal colon
were stapled flat onto cardboard with the mucosal side
up and fixed for 24 h in 10 % neutral-buffered formalin.
Tissue was then dehydrated, embedded in paraffin, and
standard hematoxylin/eosin staining was performed on
5-μm thick sections. Five sections at least 50 μm apart
per colon were scored as described before [19]. Mucosal
architecture, muscle thickness, leukocyte infiltration were
each scored with 0–3 points where 0 depicts normal colon
and 3 the maximally affected colon. The absence of goblet
cells scored 1 point. The total score index for one colon
was the sum of these subscores and had a maximum of 9.
Neutrophil isolation and HUVEC culture
Neutrophils were isolated as previously described [20].
Briefly, blood from healthy adult donors was drawn into
a heparinized syringe, and allowed to settle on half of its
volume of 6 % dextran for 1 h at room temperature.
Erythrocytes were removed by hypotonic lysis, and gran-
ulocytes were further purified by density centrifugation
on lymphoprep 1077. Endothelial cells (HUVEC) were
isolated from human umbilical cords (Foothills Hospital,
Calgary, Canada) as previously described [21] and main-
tained in M199 medium (Invitrogen, Carlsbad, CA) con-
taining 20 % human serum. Only the first passage of
cells was used for the experiments. All procedures
requiring human subjects were approved by The Uni-
versity of Calgary Conjoint Health Research Ethics
Board. Study participants provided written consent for
donation of their biological samples for research. The
colonic epithelial cell line LoVo was purchased from
ATCC (# CCL-229) and cultured in F-12 K Medium
(ATCC) supplemented with 10 % fetal bovine serum.
Chemotaxis assay
2.5 × 105 neutrophils were incubated with Abn-CBD
and/or O-1918 at the concentrations indicated for
30 min and pipetted into the top chamber of 5 μm pore
Transwells® (Corning Life Sciences, Union City, CA).
Cells were allowed to migrate through the pores to the
lower chamber of the wells containing the chemokine
IL-8 at the effective concentration of 10nM. This subopti-
mal IL-8 concentration was chosen so that that anything
that interfered with IL-8’s ability to induce a response
could be observed. A random migration control (no
stimulus) was run in every experiment. The experiment
was stopped after 3 h. Three non-overlapping digital
images of the bottom of each chamber were taken using
a light microscope, and adherent cells were counted.
Neutrophil recruitment under flow conditions
Interactions between endothelial cells and freshly isolated
human neutrophils were examined under flow conditions. A
parallel plate flow chamber from Glycotech (Gaithersburg,
MD, USA) was used to mimic physiologic flow conditions.
Neutrophil accumulation and transmigration were de-
termined as previously described for eosinophils [20].
Briefly, endothelial cell monolayers were incubated with
10 ng/ml of TNF-α for 4 h. Either the monolayer was
also incubated with Abn-CBD or O-1918 for 4 h, or
neutrophils were treated with the drugs 1 h prior to the
experiment at indicated concentrations. After TNF-α stimu-
lation, neutrophils (1 × 106/mL) were perfused across the
monolayer at 1 dyn/cm2 using the parallel plate flow cham-
ber. After 4 min of perfusion, the inlet line was transferred
to Hank’s balanced salt solution (HBSS), to prevent the
binding of new neutrophils, and buffer was perfused for
an additional 4 min. Interactions between neutrophils
and endothelial cells were visualized on a Zeiss Axiovert
100 microscope using either a 10X/0.25NA or 40X/0.60NA
phase-contrast objective and recorded via a charge-coupled
device camera (KP-M1U; Hitachi Denshi, Ltd.). The total
number of cells accumulated on the monolayer was de-
termined between 4 and 5 min of perfusion and the
number of transmigrated cells were determined between 6
and 7 min. 4–10 fields of view were examined for each
condition.
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Immunohistochemistry
Neutrophils on glass coverslips were fixed with 2 %
paraformaldehyde in HBSS, then washed with HBSS and
blocked for 1 h with 1 % human serum albumin in
HBSS. Cells were stained with anti-GPR18 antibody or
isotype control for 1 h (1:300 in HBSS), then washed
and incubated with the secondary FITC-conjugated de-
tection antibody (1:1000) for 1 h. Cells were mounted
with Hoechst 33258 (Sigma-Aldrich, Oakville, Ontario,
Canada).
Scratch wound healing assay
Single-path wound healing experiments were performed
as described [22]. Briefly, LoVo cells and HUVEC were
grown to confluence in 6-well dishes. A day prior to the
experiment cells were starved with serum-deprived medium
or medium with low serum content (for HUVEC). Wounds
were made by dragging a sterile 10 μl pipette tip across the
monolayer to create a cell-free path ~1 mm wide, and cells
were incubated with Abn-CBD and/or O-1918 at the con-
centrations indicated for 20 h, or at 1 μM, where there is no
indication. Pictures of the wounds at 0 h and 20 h were
taken using an inverted microscope with mounted camera
at x100 magnification (Olympus, Center Valley, PA), and
quantification of cell migration into the wounded area was
done using the MetaMorph® Analysis Software. 3-4 fields of
view were analyzed per well.
Statistical analysis
For statistical analysis a Student’s t-test or one-way
ANOVA with Tukey’s post-hoc test was performed using
the GraphPad Prism software (La Jolla, CA, USA). Sig-
nificance was set at p ≤ 0.05. Data are presented as mean
values ± the standard error of the means (SEM).
Results
Abn-CBD attenuates the degree of colitis
Four days after the induction of colitis, mice showed se-
vere macroscopic colonic damage and inflammation
(Fig. 1a). This was reduced by treatment with Abn-CBD
(5 mg/kg, i.p., administered twice a day), (Fig. 1a).
TNBS-induced weight loss during the experiment was
not altered by administration of Abn-CBD (Additional
file 1: Figure S1). MPO activity was significantly higher
in colitic mice compared to controls and Abn-CBD
treated colitic mice (Fig. 1b), indicating that Abn-CBD
either inhibits inflammatory neutrophil recruitment or
accelerates clearance of neutrophils from the tissue, thus
reducing the inflammatory response. The selective Abn-
CBD antagonist O-1918 (5 mg/kg) was injected 30 min
before treatment with Abn-CBD. O-1918 does not bind
to either CB1 or CB2 receptors, but has been shown to
inhibit Abn-CBD induced vasorelaxation through one or
more GPCR [23]. O-1918 administration inhibited the
beneficial effects of Abn-CBD on macroscopic damage
(Fig. 1a). Interestingly, O-1918-treated mice exhibited
even greater colon damage than control mice. The same
inhibitory effect of O-1918 was observed when examin-
ing MPO activity (Fig. 1b). Abn-CBD +O-1918 adminis-
tration resulted in MPO levels similar to the colons of
untreated colitic mice. Again, MPO activity was slightly
higher in O-1918 treated groups than in the untreated
group.
Protective effects of Abn-CBD in TNBS-induced colitis are
CB1/CB2 independent
In order to investigate if the effects of abn-CBD were
mediated by CB receptors, Abn-CBD was next tested in
conjunction with AM251 and AM630, which are select-
ive inverse agonists of CB1 and CB2, respectively. Treat-

























Fig. 1 The effects of Abn-CBD treatment on macroscopic damage
score and MPO activity. TNBS-treated mice were given O-1918 (5 mg/kg)
and/or Abn-CBD (5 mg/kg) twice daily for 3 days. Macroscopic damage
score (a) and myeloperoxidase activity (b) were determined at the end
of the experiment, 24 h after the last dose of drug. Abn-CBD significantly
reduced macroscopic damage and MPO activity, and effect that was
blocked by O-1918. Data were analyzed with one-way ANOVA with
Tukey’s post-hoc test. *, p < 0.05 when compared to control and
Abn-CBD + O-1918 (a and b) and when compared to O-1918
(b); n ≥ 10/group
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the injection of Abn-CBD did not alter the protective
properties of the latter, as assessed macroscopically
(Fig. 2a). The reduction of MPO activity caused by Abn-
CBD was not affected by the CB2 antagonist AM630
(Fig. 2b), but no significant change in MPO activity were
seen in colons of mice treated with AM251, when com-
pared to Abn-CBD or control (Fig. 2b).
The microscopic colitis score was significantly lower
in mice treated with Abn-CBD, and the protective effect
was inhibited by addition of O-1918 (Fig. 3a). Histological
sections of the colonic epithelium from Abn-CBD treated
mice displayed partially preserved crypt morphology
(Fig. 3c), whereas O-1918 with or without Abn-CBD in-
creased abnormal mucosal architecture, lacking most of
the goblet cells. Abn-CBD improved the histological
appearance (Fig. 3b). This effect was reduced by pre-
treatment with AM251, while AM630 was unable to re-
verse the effects of Abn-CBD (Fig. 3b and c).
Abn-CBD inhibits inflammatory neutrophil recruitment
Neutrophil infiltration is a prominent feature of inflamma-
tory diseases [24–28], hence experiments were performed
to investigate the effect of Abn-CBD on neutrophil re-
cruitment. First, the effect of Abn-CBD on neutrophil
chemotaxis towards the chemokine IL-8 was examined.
Incubation of freshly isolated human neutrophils with
1 μM Abn-CBD significantly reduced their migration to-
wards 10 nM IL-8, and co-incubation with O-1918 (1 μM)
restored the chemotactic activity (Fig. 4). This result dem-
onstrated a direct effect of Abn-CBD on neutrophils.
Using flow chambers with confluent HUVEC mono-
layers, inflammatory neutrophil recruitment was assessed
under physiological flow conditions. This experimental
set-up can be used to mimic the extravasation of neutro-
phils from the blood stream into the inflamed tissue. It
also allows visualization of the different stages of neutro-
phil recruitment- rolling, adhesion, and transmigration -
which all require distinct and overlapping molecular
signalling events [29]. In this experiment, accumulation
of neutrophils on inflamed endothelium, i.e. the sum of
slow-rolling and firmly adhered neutrophils, was assessed,
as well as the number of transmigrated neutrophils. The
incubation of the TNF-α stimulated HUVEC monolayer
with Abn-CBD (10 nM to 1 μM) did not alter the accu-
mulation of neutrophils (Fig. 5a). However, when neutro-
phils were incubated with Abn-CBD (1 μM) 15 min prior
to perfusion over the monolayer, cell accumulation was
significantly decreased (Fig. 5b). Moreover, this inhibitory
effect of Abn-CBD was antagonized by O-1918 (1 μM).
The same was true for the transmigration rate of neutro-
phils (Fig. 5c). Fewer transmigrated cells were observed,
when neutrophils were pre-treated with Abn-CBD
(1 μM), while addition of O-1918 restored the neutro-
phil transmigration rate to control values. Abn-CBD ef-
fects may be conferred by the putative Abn-CBD
receptor GPR18, which is expressed in these cells as
shown by immunohistochemistry (Fig. 6).
Abn-CBD promotes wound healing in endothelial and
colonic epithelial cells
Endothelial and epithelial integrity is crucial for preserving
vascular and intestinal homeostasis [30, 31]. IBD is char-
acterized by ulceration and impairment of the intestinal
epithelial barrier [32], and cannabinoids have been shown
to promote wound healing of epithelial cells in a CB1
dependent manner [33]. Therefore we tested if Abn-CBD





































Fig. 2 The effects of Abn-CBD treatment in the presence of CB an-
tagonists on macroscopic damage score and MPO activity. TNBS-
treated mice were given AM251, AM630 and/or Abn-CBD (all at
5 mg/kg) twice daily for 3 days. Macroscopic damage score (a) and
myeloperoxidase activity (b) were determined at the end of the ex-
periment, 24 h after the last dose of drug. Abn-CBD treatment and
Abn-CBD + AM251 or AM630 significantly decreased the damage
score. Myeoloperoxidase activity was significantly decreased with
Abn-CBD. Data were analyzed with one-way ANOVA with Tukey’s
post-hoc test *, p < 0.05 and **, p < 0.01 when compared to
controls; n = 4-5/group
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Treatment of wounded, serum-deprived HUVEC and
LoVo colonic epithelial cells with Abn-CBD caused mi-
gration of cells into the wounded area, which was most
pronounced at the highest used concentration of 1 μM
(Figs. 7a and 8). Abn-CBD wound healing in HUVEC
was not significantly inhibited by the addition of O-1918
(Fig. 7a). In LoVo epithelial cells, addition of O-1918 sig-
nificantly inhibited the Abn-CBD induced cell migration,
(Figs. 7b and 8).
Discussion
The incidence and prevalence of ulcerative colitis and
Crohn’s disease is increasing over time and in different
regions of the world, suggesting that IBD is an emerging
global disease [34]. Numerous studies have revealed that
endocannabinoid levels, and the expression of CB1 and
CB2 receptors are increased in IBD patients and that the
endocannabinoid system may play a protective role in
the development of colitis [35, 36]. Moreover, other stud-
ies suggest that cannabinoids may exert anti-inflammatory
effects in cardiovascular disease (reviewed in [37]), the
number one cause of death globally [38]. Therefore, can-
nabinoids that exert effects through the endocannabinoid
system, but also through novel receptors may have thera-
peutic potential in inflammatory diseases, especially if the
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Fig. 3 The effects of Abn-CBD treatment on microscopic damage score and histology. TNBS-treated mice were given O-1918, AM251, AM630 (all
at 5 mg/kg) and/or Abn-CBD (5 mg/kg) twice daily for 3 days. Microscopic damage score (a and b) and histological appearance of the hematoxylin/
eosin stained tissue (c) were determined at the end of the experiment, 24 h after the last dose of drug. TNBS-treated mice displayed severe mucosal
damage as well as an increase in lymphocyte and neutrophil infiltration. a Mucosal damage was significantly reduced by Abn-CBD treatment
and reversed by addition of O-1918; *, p < 0.05, when compared to any other treatment group. b Mucosal damage was significantly reduced
by Abn-CBD treatment and partly reversed by administration of AM251; *, p < 0.05, when compared to TNBS alone. Data were analyzed with
one-way ANOVA with Tukey’s post-hoc test, n = 4-5/group. Scale bar in C. = 100 μm
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In these studies we examined the therapeutic potential
of the non-cannabinoid CBD analogue Abn-CBD for the
treatment of inflammatory conditions of the gastrointes-
tinal tract. Here we show that Abn-CBD treatment re-
sulted in a 20–30 % reduction of TNBS-induced colitis
in mice, hence Abn-CBD is less effective than previously
studied cannabinoid receptor agonists and the atypical
cannabinoid O-1602, which all reduced TNBS-induced
colitis by 35–55 % [9, 17].
The beneficial effects of Abn-CBD were completely
inhibited by O-1918, the antagonist for the putative
Abn-CBD receptor, suggesting this was a receptor-
mediated effect. Interestingly, O-1918 administration alone
increased colitis scores and MPO activity beyond that of
controls, which suggests that the actions of an en-
dogenously active anti-inflammatory endocannabinoid
were inhibited by O-1918. A previous study showed
that O-1918 inhibits the activation of an “endothelial
anandamide receptor”, and thus counteracting anandamide-
induced vasorelaxation [23]. It has also been demonstrated
that anandamide is protective in experimental colitis, and
that endogenous levels of anandamide are elevated in IBD
patients [39]. Therefore it seems likely that the administra-
tion of O-1918 not only blocked the effects of Abn-CBD,
but also the effects of anandamide, causing more severe
colon damage. We investigated the potential role of CB re-
ceptors in the mechanism of action of Abn-CBD. Neither
CB1 nor CB2 receptor antagonists reversed the action of
Abn-CBD when assessed at the macroscopic level. Previ-
ously it has been shown that CB2 receptor inhibition by
AM630 exacerbates experimentally induced colitis [17]. It
seems that Abn-CBD treatment can compensate for the
CB2 receptor inhibition by AM630, as the protective effect























Fig. 4 The effects of Abn-CBD on neutrophil chemotaxis. Neutrophils
were incubated with Abn-CBD and/or O-1918 and pipetted into the
top chamber of 5 μm Transwells (2 × 105/well). Migration towards IL-8
(10 nM) was assessed after 3 h by counting adherent neutrophils at
the bottom of the chamber (3 non-overlapping fields/well). The open
bar depicts random migration without an IL-8 stimulus. Abn-CBD
significantly reduced neutrophil chemotaxis, an effect that was
blocked by O-1918. Data were analyzed with one-way ANOVA with
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Fig. 5 The effects of Abn-CBD on neutrophil recruitment assessed
using a parallel plate flow chamber assay. HUVEC monolayers were
activated with TNF-α (10 nM) 4 h prior to the experiment. a Abn-CBD
was added to the HUVEC for 1 h and freshly isolated neutrophils were
perfused over the monolayer for 4 min. b Using a different approach
neutrophils were treated with Abn-CBD and O-1918 for 15 min and
then perfused over the HUVEC monolayer, neutrophil accumulation
was then assessed after 4 min of perfusion, and c transmigration of
neutrophils through the monolayer was determined after 6 min.
Neutrophil accumulation (after 4 min) and transmigration (after 6 min)
was significantly decreased, when neutrophils were incubated with
Abn-CBD. *, p < 0.05 and **, p < 0.01 when compared to control,
Abn-CBD + O-1918 and O-1918; n = 5/group
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The microscopic damage assessment revealed a slight in-
hibitory effect of AM251, which binds to CB1 and thereby
inhibiting the receptor’s activation [40]. AM251 has also
been described to activate GPR55 [41], which is also a ligand
for Abn-CBD, though Abn-CBD has a much higher EC50
for that receptor [6]. Therefore, a subtle Abn-CBD effect
conveyed by GPR55 may be antagonized by AM251.
In order to elucidate the effects of Abn-CBD we
assessed wound healing and neutrophil recruitment.
These experiments are important as endothelial dysfunc-
tion, delayed wound healing and neutrophil infiltration
are key features of chronic inflammatory diseases, such as
cardiovascular disease and IBD [24, 42–45]. Abn-CBD
increased the wound healing capacity of HUVEC. This
protective effect was slightly inhibited by the antagonist
O-1918. Abn-CBD-induced wound healing of the co-
lonic epithelial cell line LoVo was completely inhibited
by O-1918, suggesting that Abn-CBD acts, at least partly
through a different, O-1918-independent receptor in the
endothelial cells.
In experiments to investigate the effects of Abn-CBD
on neutrophil chemotaxis, IL-8 was used as neutrophil
attractant, as this chemokine is highly expressed in the
inflamed mucosa of IBD patients and also in uninflamed
specimens from Crohn’s disease patients [46, 47]. The
inhibitory effect of Abn-CBD on neutrophil chemotaxis
was completely reversed by the antagonist O-1918 not
only in the static chemotaxis assay, but also in a more
physiologic neutrophil recruitment assay under flow con-
ditions. Here, neutrophil activation and arrest triggered by
inflamed endothelium was inhibited, when neutrophils
were pre-treated with Abn-CBD, but not when the
HUVEC monolayer was pre-treated with Abn-CBD.
Abn-CBD had no significant effect on the pro-inflammatory
actions of TNF-α on the endothelium. The process of
neutrophil extravasation from the blood stream to sites
of inflammation involves the rolling of the cells on the
endothelium, firm arrest of the neutrophil, and trans-





Fig. 6 Fluorescence micrographs of GPR18 immunoreactivity. Neutrophils on glass coverslips were fixed with 2 % paraformaldehyde in HBSS and
stained with anti-GPR18 antibody (right panel) or isotype control (left panel), then washed and incubated with the secondary FITC-conjugated
detection antibody (green). Cells were mounted with Hoechst 33258 (Sigma-Aldrich, Oakville, Ontario, Canada) (blue). No immunoreactivity was






























Fig. 7 The effects of Abn-CBD treatment on wound healing. HUVEC
and LoVo cells were grown to confluence in 6 well plates. Then a
scratch wound was made with a pipet tip. a HUVEC cells were incubated
with the respective concentrations of Abn-CBD and O-1918. Wound area
size was measured at 0 and 20 h. Abn-CBD significantly accelerated
wound closure in HUVEC. Additional treatment with the O-1918 did not
reverse this effect. b For incubation of LoVo cells, the effective dose for
Abn-CBD (1 μM) was used. Wound area was measured at 0 and 20 h.
Abn-CBD significantly accelerated wound closure. The Abn-CBD effect
was reversed by addition of the antagonist O-1918. Data were analyzed
with one-way ANOVA with Tukey’s post-hoc test. *, p < 0.05 when
compared to any other treatment; n = 5-7/group
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steps require intricate overlapping and distinct molecu-
lar events to take place, such as activation of integrins,
and increased expression of adhesion molecules and
chemokines [29]. In summary, rolling of neutrophils on
the endothelium is selectin-mediated and followed by
chemokine-triggered activation of leukocytes and their
integrin-dependent arrest. Chemokines that lead to ac-
tivation and adherence of neutrophils are produced by
the inflamed endothelium and immobilized on the
endothelial cell-surface [48]. The last step of the extrava-
sation process, the transmigration or diapedesis of the
neutrophil through the endothelium, also involves redistri-
bution of integrin-adhesion molecule clusters [49]. As
incubation of the HUVEC monolayer did not alter neu-
trophil accumulation, but treatment of neutrophils did,
we reason that Abn-CBD interferes with the chemokine-
mediated inside-out signaling in neutrophils through
GPCRs, which would otherwise lead to an increase of af-
finity and avidity of integrins. This assumption concurs
with the fact that neutrophil rolling (selectin-dependent)
was not affected by Abn-CBD (data not shown), but trans-
migration (integrin-dependent) was. The identification of
the inhibitory pathway and identification of the affected
integrin-ligand interactions go beyond the scope of this
study, but we speculate that Abn-CBD effects may be con-
ferred by GPR18, the putative Abn-CBD receptor [10], as
Fig. 8 The effects of Abn-CBD treatment on wound healing. HUVEC and LoVo cells were grown to confluence in 6 well plates. Then a scratch
wound was made with a pipet tip. Wound area was measured at 0 and 20 h. Scale bar = 100 μm. Abn-CBD treatment accelerated wound healing
and O-1918 addition reversed the Abn-CBD effect (see Fig. 7 for detailed results)
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its expression on these cells was confirmed by immuno-
histochemistry. Furthermore the inhibition of neutrophil
chemotaxis by other endocannabinoids were shown to be
independent of CB1 and CB2 receptors [50].
Conclusion
This study demonstrates that Abn-CBD promotes epi-
thelial, and endothelial wound healing in vitro. Abn-CBD
drastically interferes with the inflammatory recruitment of
neutrophils in vitro, and in vivo possibly through targeting
the receptor. GPR18 is a strong candidate involved in the
mechanism by which Abn-CBD improves the outcome of
colitis, since attenuation of TNBS-induced colitis by Abn-
CBD was not reversed by CB1/CB2 antagonists on a
macroscopic level. These studies point to the potential of
non-psychotropic cannabinoids as potential therapeutics
for the treatment of IBD, but may also be of importance
in other chronic inflammatory diseases like cardiovascular
disease, as suggested by Abn-CBD’s strong effect on endo-
thelial cells.
Additional file
Additional file 1: Figure S1 Weight loss in animals with colitis. O-1918
(5 mg/kg) and/or Abn-CBD (5 mg/kg) were given twice daily for 3 days
to TNBS-treated mice. Weight of the animals was recorded daily. All ani-
mals lost weight throughout the duration of the experiment. Abn-CBD
treatment did not decrease weight loss. No significant differences in
weight loss were observed. (PPTX 3237 kb)
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